{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:15:01Z","timestamp":1769627701662,"version":"3.49.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) infects nearly one-fourth of people with human immunodeficiency virus (HIV). The role of direct-acting antivirals (DAAs) on immune activation in people with HIV (PWH) and HCV is poorly understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We quantified plasma HCV RNA and CXCL10 in persons with HCV monoinfection versus HIV\/HCV coinfection receiving sofosbuvir-velpatasvir. Single-cell laser capture microdissection was applied to liver biopsies obtained before and within 4\u20137 days of DAA initiation to estimate HCV clearance and changes in interferon-stimulated genes (ISGs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We enrolled 10 people with chronic genotype 1a HCV: 5 were PWH with ART-suppressed viremia and CD4+ T cell counts &amp;gt;200 cells\/\u00b5L. First- and second-phase plasma HCV RNA kinetics were not different between groups. Median (min\u2013max) proportions of infected hepatocytes at biopsy 1 were 0.06 (0.01\u20130.59) in HCV monoinfection and 0.21 (0.04\u20130.87) in HIV\/HCV coinfection and did not differ. Participants had lower intracellular HCV RNA levels at biopsy 2. CXCL10 levels declined in both groups but were higher in coinfection than in monoinfection even at the end of treatment. The proportion of cells expressing ISGs diminished in monoinfection but increased in coinfection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Whereas DAAs rapidly cleared intrahepatic HCV in both groups, immune activation was slower to diminish in PWH. Residual immune activation in PWH warrants further exploration.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT02938013.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae598","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:24:50Z","timestamp":1733858690000},"page":"1299-1308","source":"Crossref","is-referenced-by-count":1,"title":["Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation"],"prefix":"10.1093","volume":"231","author":[{"given":"Jaiprasath","family":"Sachithanandham","sequence":"first","affiliation":[{"name":"W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Public Health , Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Leep-Lazar","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Quinn","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Bowden","sequence":"additional","affiliation":[{"name":"Applied Physics Laboratory, Johns Hopkins University , Laurel, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanthy","family":"Balasubramaniam","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Ward","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruy M","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Theoretical Biology and Biophysics, Los Alamos National Laboratory , Los Alamos, New Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6143-3104","authenticated-orcid":false,"given":"Ashwin","family":"Balagopal","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"2025060208124358200_jiae598-B1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.15585\/mmwr.mm6618a2","article-title":"State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs\u2014United States, 2015\u20132016","volume":"66","author":"Campbell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025060208124358200_jiae598-B2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"2025060208124358200_jiae598-B3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/QAD.0b013e3282f10de9","article-title":"Rapid fibrosis progression among HIV\/hepatitis C virus-co-infected adults","volume":"21","author":"Sulkowski","year":"2007","journal-title":"AIDS"},{"key":"2025060208124358200_jiae598-B4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/j.gastro.2010.11.052","article-title":"Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus","volume":"140","author":"Woreta","year":"2011","journal-title":"Gastroenterology"},{"key":"2025060208124358200_jiae598-B5","doi-asserted-by":"crossref","first-page":"726419","DOI":"10.3389\/fimmu.2021.726419","article-title":"A tale of two viruses: immunological insights into HCV\/HIV coinfection","volume":"12","author":"Gobran","year":"2021","journal-title":"Front Immunol"},{"key":"2025060208124358200_jiae598-B6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.aids.0000163935.99401.25","article-title":"Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus","volume":"19","author":"Sulkowski","year":"2005","journal-title":"AIDS"},{"key":"2025060208124358200_jiae598-B7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2008.03.022","article-title":"Human immunodeficiency virus\u2013related microbial translocation and progression of hepatitis C","volume":"135","author":"Balagopal","year":"2008","journal-title":"Gastroenterology"},{"key":"2025060208124358200_jiae598-B8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/587696","article-title":"CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus","volume":"197","author":"Kovacs","year":"2008","journal-title":"J Infect Dis"},{"key":"2025060208124358200_jiae598-B9","doi-asserted-by":"crossref","first-page":"11407","DOI":"10.1128\/JVI.01211-09","article-title":"High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment","volume":"83","author":"Gonzalez","year":"2009","journal-title":"J Virol"},{"key":"2025060208124358200_jiae598-B10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/hep.27158","article-title":"Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus\/hepatitis C virus coinfected patients","volume":"60","author":"Balagopal","year":"2014","journal-title":"Hepatology"},{"key":"2025060208124358200_jiae598-B11","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/QAD.0000000000001480","article-title":"Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals","volume":"31","author":"El-Diwany","year":"2017","journal-title":"AIDS"},{"key":"2025060208124358200_jiae598-B12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/infdis\/jiad025","article-title":"Second-phase hepatitis C plasma viral kinetics directly reflects reduced intrahepatic burden of HCV","volume":"228","author":"Sachithanandham","year":"2023","journal-title":"J Infect Dis"},{"key":"2025060208124358200_jiae598-B13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/jiaa126","article-title":"Intrahepatic viral kinetics during direct-acting antivirals for hepatitis C in human immunodeficiency virus coinfection: the AIDS Clinical Trials Group A5335S substudy","volume":"222","author":"Balagopal","year":"2020","journal-title":"J Infect Dis"},{"key":"2025060208124358200_jiae598-B14","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1053\/j.gastro.2013.08.034","article-title":"Use of laser capture microdissection to map hepatitis C virus\u2013positive hepatocytes in human liver","volume":"145","author":"Kandathil","year":"2013","journal-title":"Gastroenterology"},{"key":"2025060208124358200_jiae598-B15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/jvh.13429","article-title":"HIV influences clustering and intracellular replication of hepatitis C virus","volume":"28","author":"Goyal","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025060208124358200_jiae598-B16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"2025060208124358200_jiae598-B17","doi-asserted-by":"crossref","first-page":"112405","DOI":"10.1016\/j.biopha.2021.112405","article-title":"HCV eradication with DAAs differently affects HIV males and females: a whole miRNA sequencing characterization","volume":"145","author":"Valle-Millares","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025060208124358200_jiae598-B18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/infdis\/jiy136","article-title":"Eradication of hepatitis C virus (HCV) reduces immune activation, microbial translocation, and the HIV DNA level in HIV\/HCV-coinfected patients","volume":"218","author":"L\u00f3pez-Cort\u00e9s","year":"2018","journal-title":"J Infect Dis"},{"key":"2025060208124358200_jiae598-B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2014.127","article-title":"Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection","volume":"13","author":"Wong","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"2025060208124358200_jiae598-B20","doi-asserted-by":"crossref","first-page":"723196","DOI":"10.3389\/fimmu.2021.723196","article-title":"HCV cure with direct-acting antivirals improves liver and immunological markers in HIV\/HCV-coinfected patients","volume":"12","author":"Brochado-Kith","year":"2021","journal-title":"Front Immunol"},{"key":"2025060208124358200_jiae598-B21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med"},{"key":"2025060208124358200_jiae598-B22","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"2025060208124358200_jiae598-B23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/cid\/ciw379","article-title":"All-oral direct-acting antiviral regimens in HIV\/hepatitis C virus\u2013coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH cohort","volume":"63","author":"Sogni","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025060208124358200_jiae598-B24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"2025060208124358200_jiae598-B25","doi-asserted-by":"crossref","first-page":"246ra98","DOI":"10.1126\/scitranslmed.3008195","article-title":"Modulation of HCV replication after combination antiretroviral therapy in HCV\/HIV co-infected patients","volume":"6","author":"Sherman","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025060208124358200_jiae598-B26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00002030-200209270-00008","article-title":"Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects","volume":"16","author":"Chung","year":"2002","journal-title":"AIDS"},{"key":"2025060208124358200_jiae598-B27","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","article-title":"Interferon signaling and treatment outcome in chronic hepatitis C","volume":"105","author":"Sarasin-Filipowicz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025060208124358200_jiae598-B28","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J Clin Invest"},{"key":"2025060208124358200_jiae598-B29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/cid\/ciw771","article-title":"Systemic elevation of proinflammatory interleukin 18 in HIV\/HCV coinfection versus HIV or HCV monoinfection","volume":"64","author":"Veenhuis","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025060208124358200_jiae598-B30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/infdis\/jiaa254","article-title":"Hepatitis C virus (HCV) direct-acting antiviral therapy in persons with human immunodeficiency virus\u2013HCV genotype 1 coinfection resulting in high rate of sustained virologic response and variable in normalization of soluble markers of immune activation","volume":"222","author":"Anthony","year":"2020","journal-title":"J Infect Dis"},{"key":"2025060208124358200_jiae598-B31","doi-asserted-by":"crossref","first-page":"ofab079","DOI":"10.1093\/ofid\/ofab079","article-title":"T-cell activation is correlated with monocyte activation in HCV\/HIV coinfection and declines during HCV direct-acting antiviral therapy","volume":"8","author":"Auma","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025060208124358200_jiae598-B32","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3390\/pathogens10111488","article-title":"Short- and long-term immunological responses in chronic HCV\/HIV co-infected compared to HCV mono-infected patients after DAA therapy","volume":"10","author":"Farcomeni","year":"2021","journal-title":"Pathogens"},{"key":"2025060208124358200_jiae598-B33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/aid.2010.0329","article-title":"HIV variability in the liver and evidence of possible compartmentalization","volume":"27","author":"Blackard","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025060208124358200_jiae598-B34","doi-asserted-by":"crossref","first-page":"104391","DOI":"10.1016\/j.ebiom.2022.104391","article-title":"HIV DNA persists in hepatocytes in people with HIV\u2013hepatitis B co-infection on antiretroviral therapy","volume":"87","author":"Zerbato","year":"2023","journal-title":"EBioMedicine"},{"key":"2025060208124358200_jiae598-B35","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.32111","article-title":"Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance","volume":"75","author":"Hlady","year":"2022","journal-title":"Hepatology"},{"key":"2025060208124358200_jiae598-B36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/pathogens10010044","article-title":"Liver abnormalities after elimination of HCV infection: persistent epigenetic and immunological perturbations post-cure","volume":"10","author":"Polyak","year":"2021","journal-title":"Pathogens"},{"key":"2025060208124358200_jiae598-B37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41590-020-00817-w","article-title":"Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection","volume":"22","author":"Hensel","year":"2021","journal-title":"Nat Immunol"},{"key":"2025060208124358200_jiae598-B38","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"2025060208124358200_jiae598-B39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-1-4939-8976-8_13","article-title":"Studying the hepatitis C virus-induced epigenetic signature after cure with direct-acting antivirals","volume":"1911","author":"Perez","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2025060208124358200_jiae598-B40","doi-asserted-by":"crossref","first-page":"e01777-20","DOI":"10.1128\/JVI.01777-20","article-title":"People with HIV-1 demonstrate type 1 interferon refractoriness associated with upregulated USP18","volume":"95","author":"Sugawara","year":"2021","journal-title":"J Virol"},{"key":"2025060208124358200_jiae598-B41","doi-asserted-by":"crossref","first-page":"916599","DOI":"10.3389\/fimmu.2022.916599","article-title":"Plasma vesicular miR-155 as a biomarker of immune activation in antiretroviral treated people living with HIV","volume":"13","author":"Bazi\u00e9","year":"2022","journal-title":"Front Immunol"},{"key":"2025060208124358200_jiae598-B42","first-page":"ciac767","article-title":"Sex-differences in subclinical atherosclerosis and systemic immune activation\/inflammation among people with HIV in the U.S","volume":"14","author":"Zanni","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025060208124358200_jiae598-B43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/QAI.0000000000003080","article-title":"Persistent CD38 expression on CD8+ T lymphocytes contributes to altered mitochondrial function and chronic inflammation in people with HIV, despite ART","volume":"91","author":"Mathur","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025060208124358200_jiae598-B44","doi-asserted-by":"crossref","first-page":"e13681","DOI":"10.1111\/acel.13681","article-title":"Inflammatory and immune markers in HIV-infected older adults on long-term antiretroviral therapy: persistent elevation of sCD14 and of proinflammatory effector memory T cells","volume":"21","author":"Watanabe","year":"2022","journal-title":"Aging Cell"},{"key":"2025060208124358200_jiae598-B45","doi-asserted-by":"crossref","first-page":"e0058822","DOI":"10.1128\/jvi.00588-22","article-title":"Markers of immune activation and inflammation are associated with higher levels of genetically-intact HIV in HIV-HBV co-infected individuals","volume":"96","author":"Wang","year":"2022","journal-title":"J Virol"},{"key":"2025060208124358200_jiae598-B46","doi-asserted-by":"crossref","first-page":"104182","DOI":"10.1016\/j.ebiom.2022.104182","article-title":"Dissecting drivers of immune activation in chronic HIV-1 infection","volume":"83","author":"Streeck","year":"2022","journal-title":"EBioMedicine"},{"key":"2025060208124358200_jiae598-B47","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.3390\/jcm11133579","article-title":"Dynamics of HIV reservoir and HIV-1 viral splicing in HCV-exposed individuals after elimination with DAAs or spontaneous clearance","volume":"11","author":"Mart\u00ednez-Rom\u00e1n","year":"2022","journal-title":"J Clin Med"},{"key":"2025060208124358200_jiae598-B48","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1097\/QAD.0000000000003301","article-title":"No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART","volume":"36","author":"Ward","year":"2022","journal-title":"AIDS"},{"key":"2025060208124358200_jiae598-B49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/QAI.0000000000001158","article-title":"Treatment as prevention: characterization of partner infections in the HIV Prevention Trials Network 052 trial","volume":"74","author":"Eshleman","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025060208124358200_jiae598-B50","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/infdis\/jir651","article-title":"Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial","volume":"204","author":"Eshleman","year":"2011","journal-title":"J Infect Dis"},{"key":"2025060208124358200_jiae598-B51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/JLB.3A0717-294RR","article-title":"Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls","volume":"103","author":"Williams","year":"2018","journal-title":"J Leukoc Biol"},{"key":"2025060208124358200_jiae598-B52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/infdis\/jir214","article-title":"Soluble CD163 made by monocyte\/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy","volume":"204","author":"Burdo","year":"2011","journal-title":"J Infect Dis"},{"key":"2025060208124358200_jiae598-B53","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41598-019-41788-9","article-title":"HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study","volume":"9","author":"L\u00f3pez-Huertas","year":"2019","journal-title":"Sci Rep"},{"key":"2025060208124358200_jiae598-B54","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1038\/s41598-022-08871-0","article-title":"HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy","volume":"12","author":"\u00c1lvarez","year":"2022","journal-title":"Sci Rep"},{"key":"2025060208124358200_jiae598-B55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/QAD.0000000000003116","article-title":"Antiretroviral therapy for HIV and intrahepatic hepatitis C virus replication","volume":"36","author":"Quinn","year":"2022","journal-title":"AIDS"},{"key":"2025060208124358200_jiae598-B56","doi-asserted-by":"crossref","first-page":"e1003934","DOI":"10.1371\/journal.pcbi.1003934","article-title":"Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes","volume":"10","author":"Graw","year":"2014","journal-title":"PLoS Comput Biol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae598\/61217173\/jiae598.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/5\/1299\/61217173\/jiae598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/5\/1299\/61217173\/jiae598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:12:58Z","timestamp":1748866378000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/5\/1299\/7916519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae598","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,15]]},"published":{"date-parts":[[2024,12,4]]}}}